Skip to content

Study · Ex vivo tissue · rat and guinea pig · 2004

1 result

Effect of different forms of vasoactive intestinal peptide on cAMP formation in the mammalian cerebral cortex.

Dejda A, Gendek-Kubiak H, Nowak JZ

Polish journal of pharmacology1 Jul 2004Cited by 3 (Europe PMC)

PMID15520496 (opens in a new tab)PepBankPUB-15520496
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In rat and guinea pig cortical slices, chicken VIP stimulated cAMP formation most strongly and guinea pig VIP most weakly, with mammalian VIP between them.

    In plain wordsIn lab tests on rat and guinea pig brain slices, chicken VIP raised cAMP most and guinea pig VIP least.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedcAMP formation by VIP forms
    Study

    rat, guinea pign: not reported in source

    cerebral cortical slices
    Comparator
    Other VIP forms
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.001-3 microMAs given in this study (rat, guinea pig).

    Source sentences

    Summary
    Of the tested peptides, i.e. chicken VIP (cVIP), guinea pig VIP (gpVIP) and human/rat/porcine (mammalian) VIP (mVIP), the strongest stimulator of cAMP synthesis was cVIP, and the weakest one - the gpVIP.
    1 context sentence
    Summary · context
    Chicken, guinea pig and mammalian (human/porcine/rat) vasoactive intestinal peptides (VIP; 0.001-3 microM) were compared with respect to their ability to stimulate adenosine 3', 5'-cyclic monophosphate (cAMP) formation in the cerebral cortical slices of rat and guinea pig.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.